Lv71
3458 积分 2021-07-21 加入
Reading Between the Lines: Circulating Tumor DNA Dynamics Illuminate Immunotherapy Outcomes in Lung Squamous Cell Carcinoma
11天前
已完结
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
28天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
28天前
已完结
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
28天前
已完结
GSTA1 conferred tolerance to osimertinib and provided strategies to overcome drug-tolerant persister in EGFR-mutant lung adenocarcinoma
29天前
已完结
MTAP deficiency confers resistance to cytosolic nucleic acid sensing and STING agonists
1个月前
已完结
Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma
1个月前
已完结
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
1个月前
已完结
EML4-ALK variant-specific genetic interactions shape lung tumorigenesis
1个月前
已完结
PRT3789 is a First-in-Human SMARCA2-Selective Degrader that Induces Synthetic Lethality in SMARCA4-Mutated Cancers
1个月前
已完结
皖公网安备34019202002308
